Johnson & Johnson vs Eli Lilly (JNJ vs LLY)
Side by side from their SEC filings: revenue, margins, growth, returns and valuation, plus short interest, insider activity and institutional ownership.
Johnson & Johnson is the larger company by revenue ($94.2B vs $65.2B). Eli Lilly carries the larger market value ($1.1T vs $615.9B). Eli Lilly has grown revenue faster over the last 4 fiscal years (+130.2% cumulative vs +19.6%). Johnson & Johnson trades at the lower trailing P/E (38.8x vs 42.2x).
About Johnson & Johnson
Johnson & Johnson is a global healthcare company that operates through two main segments: Innovative Medicine and MedTech. The Innovative Medicine segment develops and sells prescription medicines for various therapeutic areas including oncology, immunology, neuroscience, infectious diseases, and cardiovascular conditions. The MedTech segment designs and manufactures medical devices and products used in cardiovascular care, orthopaedics, surgery, and vision, serving healthcare professionals, hospitals, and eye care providers worldwide.
About Eli Lilly
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. Its main products include treatments for diabetes, oncology, immunology, and neuroscience conditions. The company serves healthcare providers, wholesalers, pharmacies, hospitals, and patients in approximately 90 countries.
Head to head (JNJ FY2025 vs LLY FY2025)
| Metric | JNJFY2025 | LLYFY2025 |
|---|---|---|
| Revenue | $94.19B | $65.18B |
| Revenue growth (YoY) | 6.0% | 44.7% |
| Gross margin | 67.9% | 83.0% |
| Operating margin | — | — |
| Net margin | 28.5% | 31.7% |
| Net income | $26.80B | $20.64B |
| Diluted EPS | $11.03 | $22.95 |
| FCF margin | 20.9% | — |
| ROE | 32.9% | 77.8% |
| Long-term debt / equity | 0.48× | 1.54× |
| Market cap | $615.87B | $1.12T |
| P/E | 38.8× | 42.2× |
Fundamentals are from each company’s SEC filings (JNJ FY2025, LLY FY2025). ROE is net income over fiscal-year-end equity; long-term debt / equity counts non-current term debt only. P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.
Five-year trend (as reported)
| Revenue | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| JNJ | $78.74B | $79.99B | $85.16B | $88.82B | $94.19B |
| LLY | $28.32B | $28.54B | $34.12B | $45.04B | $65.18B |
Peer standing
Where each company ranks among the 198 pharmaceutical companies, on the same scale. Each figure is ranked only against peers that report it. Percentiles describe position in the distribution, not a rating.
| Metric | JNJ | LLY |
|---|---|---|
| Gross margin | 67.9%53rd percentile of 69 | 83.0%82nd percentile of 69 |
| Net margin | 28.5%83rd percentile of 121 | 31.7%86th percentile of 121 |
| Revenue growth (YoY) | +6.0%44th percentile of 188 | +44.7%72nd percentile of 188 |
| ROE | 32.9%90th percentile of 167 | 77.8%99th percentile of 167 |
| P/E | 38.8×73rd percentile of 50 | 42.2×80th percentile of 50 |
| Long-term debt / equity | 0.48×49th percentile of 64 | 1.54×89th percentile of 64 |
| Short interest (days to cover) | 3.27d23rd percentile of 197 | 2.93d19th percentile of 197 |
Short interest
| FINRA settlement data | JNJ | LLY |
|---|---|---|
| Shares sold short | 22.1M | 7.0M |
| Change vs prior settlement | +4.2% | -6.4% |
| Days to cover | 3.27 | 2.93 |
| As of settlement | 2026-09-30 | 2026-09-30 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data; republishing or redistributing it is not permitted. Not presented as a percentage of float. No FINRA endorsement of this product is implied.
Insider activity (last 90 days)
| Form 4 activity (codes P/S) | JNJ | LLY |
|---|---|---|
| Buys | 0 | 0 |
| Sells | 10 ($67.8M) | 3 ($16.0M) |
Non-derivative purchases (code P) and sales (code S) reported on SEC Form 4, which may be open-market or private (grants, exercises and tax withholding excluded). For context, about 15% of covered companies saw any reported insider purchase (code P) in a 90-day window.
Held by the same investors
9 tracked 13F managers hold both Johnson & Johnson and Eli Lilly as of their latest quarterly filings: AQR Capital Management, Bridgewater Associates, Citadel Advisors, D. E. Shaw, Dodge & Cox, Gotham Asset Management, Millennium Management, Soros Fund Management, Two Sigma Investments. See which superinvestors hold your own portfolio with the smart money checker.
Go deeper
ABBV vs JNJABT vs JNJBMY vs JNJJNJ vs MRKJNJ vs PFEJNJ vs VRTXAll pharmaceutical stocks →All comparisons →
Track JNJ and LLY
Get an alert when either company files something material, see which superinvestors own them, and ask their filings a question with cited answers.
Start monitoring freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filings before relying on them. Comparisons are descriptive (higher or lower on a reported figure), not a rating or a recommendation. Informational only. Not investment advice.